Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years.
Covered in this story
What has happened since
- CenterPoint Energy is up 2.4% since this was published, 47 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $CNP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on CenterPoint Energy →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.